Welcome to Idorsia

Idorsia announced financial results for the first nine months of 2019

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

05 Dec 2019	Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan
19 Nov 2019	Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel
11 Nov 2019	Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019

Event	When
Full-Year 2019 Financial Results reporting*	February 6, 2020
First Quarter 2020 Financial Results reporting*	April 23, 2020
Annual General Meeting of Shareholders	May 13, 2020
Half-Year 2020 Financial Results reporting*	July 23, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 13:06:18 CET

29.10 CHF

-0.02 (-0.07 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland